Latest Insider Transactions at Regenxbio Inc. (RGNX)
This section provides a real-time view of insider transactions for Regenxbio Inc. (RGNX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of REGENXBIO Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of REGENXBIO Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 15
2021
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
252
-0.22%
|
$12,600
$50.04 P/Share
|
|
Jan 14
2021
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
11,093
-8.88%
|
$554,650
$50.03 P/Share
|
|
Jan 14
2021
|
Curran Simpson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,612
-39.55%
|
$580,600
$50.01 P/Share
|
|
Jan 14
2021
|
Curran Simpson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,612
+16.12%
|
$313,524
$27.65 P/Share
|
|
Jan 12
2021
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,200
-3.25%
|
$210,000
$50.01 P/Share
|
|
Jan 12
2021
|
Curran Simpson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
1,700
-8.74%
|
$85,000
$50.03 P/Share
|
|
Jan 12
2021
|
Curran Simpson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+8.04%
|
$32,300
$19.5 P/Share
|
|
Jan 12
2021
|
Patrick J. Christmas Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,378
-7.76%
|
$67,522
$49.15 P/Share
|
|
Jan 12
2021
|
Patrick J. Christmas Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,378
+7.2%
|
$26,182
$19.5 P/Share
|
|
Jan 11
2021
|
Patrick J. Christmas Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,122
-38.2%
|
$495,978
$49.08 P/Share
|
|
Jan 11
2021
|
Patrick J. Christmas Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,122
+16.46%
|
$151,830
$15.8 P/Share
|
|
Jan 08
2021
|
Patrick J. Christmas Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
10,000
-14.55%
|
$470,000
$47.33 P/Share
|
|
Jan 08
2021
|
Patrick J. Christmas Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+27.49%
|
$120,000
$12.1 P/Share
|
|
Jan 08
2021
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,241
-1.31%
|
$246,327
$47.36 P/Share
|
|
Jan 07
2021
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
1,500
-0.53%
|
$75,000
$50.01 P/Share
|
|
Jan 07
2021
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
1,500
+0.53%
|
$0
$0.85 P/Share
|
|
Jan 07
2021
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
10,998
-7.56%
|
$549,900
$50.0 P/Share
|
|
Jan 07
2021
|
Curran Simpson Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,185
-22.61%
|
$259,250
$50.01 P/Share
|
|
Jan 07
2021
|
Curran Simpson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,185
+18.44%
|
$98,515
$19.5 P/Share
|
|
Jan 04
2021
|
Kenneth T. Mills |
BUY
Grant, award, or other acquisition
|
Direct |
40,984
+12.69%
|
-
|
|
Jan 04
2021
|
Patrick J. Christmas Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,800
+45.74%
|
-
|
|
Jan 04
2021
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,600
+37.86%
|
-
|
|
Jan 04
2021
|
Steve Pakola Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,000
+50.0%
|
-
|
|
Jan 04
2021
|
Curran Simpson Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,800
+43.74%
|
-
|
|
Jan 04
2021
|
Vittal Vasista Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,400
+7.86%
|
-
|
|
Dec 28
2020
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
6,500
-1.32%
|
$312,000
$48.82 P/Share
|
|
Dec 28
2020
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
6,500
+2.56%
|
$0
$0.85 P/Share
|
|
Dec 24
2020
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,376
-2.48%
|
$168,800
$50.0 P/Share
|
|
Dec 23
2020
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
4,500
-1.83%
|
$225,000
$50.0 P/Share
|
|
Dec 23
2020
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+1.8%
|
$0
$0.85 P/Share
|
|
Dec 23
2020
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
21,124
-13.41%
|
$1,056,200
$50.01 P/Share
|
|
Dec 16
2020
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
15,000
-5.86%
|
$675,000
$45.0 P/Share
|
|
Dec 16
2020
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+5.54%
|
$0
$0.85 P/Share
|
|
Dec 11
2020
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
14,916
-8.65%
|
$596,640
$40.17 P/Share
|
|
Dec 10
2020
|
Kenneth T. Mills |
SELL
Open market or private sale
|
Direct |
4,500
-1.83%
|
$180,000
$40.0 P/Share
|
|
Dec 10
2020
|
Kenneth T. Mills |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+1.8%
|
$0
$0.85 P/Share
|
|
Dec 10
2020
|
Vittal Vasista Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
22,584
-11.58%
|
$903,360
$40.06 P/Share
|
|
Jun 30
2020
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
641
+7.93%
|
$19,871
$31.31 P/Share
|
|
Dec 31
2019
|
Olivier Danos Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
302
+4.25%
|
$10,268
$34.82 P/Share
|